Eric Walker, MD
Infectious Disease · Dallas, TXNPI 1659480549
Payments from drug & device makers
Across 65 payments — averaging $64.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$220
- Novo Nordisk$217
- Astellas Pharma US Inc$85
- Lilly USA, LLC$54
- Novartis$41
- plus $136 from 7 others
What the payments were for
- Speaking & faculty fees$1,50036%
- Travel & lodging$1,45135%
- Food & beverage$1,14427%
- Education$722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $3,415 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $220 |
| Novo Nordisk | 16 | $217 |
| Astellas Pharma US Inc | 2 | $85 |
| Lilly USA, LLC | 3 | $54 |
| Novartis | 3 | $41 |
| Melinta Therapeutics, LLC | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $30 |
| Amgen | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,167 in reported general payments places this provider in the 70th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 24 | $900 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Dallas
- Mezgebe BerheDallas$11M
- Mamta JainDallas$3.7M
- Elizabeth RaceDallas$1.5M
- David GreenbergDallas$1.2M
- Roger BedimoDallas$976K
- Theodoros KelesidisDallas$715K
- Uriel SandkovskyDallas$616K
- Jeremy ChowDallas$500K
- Satish MocherlaDallas$417K
- Edward DominguezDallas$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.